6-hydroxymethyl-7,8-dihydropterin

Description

2-amino-6-(hydroxymethyl)-7,8-dihydropteridin-4-one : A dihydropterin that is 7,8-dihydropteridin-4-one substituted at positions 2 and 6 by amino and hydroxymethyl groups respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-amino-6-(hydroxymethyl)-7,8-dihydropteridin-4-ol : A dihydropterin that is 7,8-dihydropteridin-4-ol substituted at positions 2 and 6 by amino and hydroxymethyl groups respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID Source	ID
PubMed CID	135398568
CHEMBL ID	1233322
CHEBI ID	17083
CHEBI ID	44841
SCHEMBL ID	230712
MeSH ID	M0475106

Synonyms (31)

Synonym
CHEMBL1233322
CHEBI:17083 ,
2-amino-6-(hydroxymethyl)-7,8-dihydropteridin-4-ol
2-amino-6-hydroxymethyl-7,8-dihydro-3h-pteridin-4-one
2-amino-4-hydroxy-6-hydroxy-methyl-dihydropteridine
2-amino-7,8-dihydro-4-hydroxy-6-(hydroxymethyl)pteridine
2-amino-4-hydroxy-6-(hydroxymethyl)dihydropteridine
3672-03-5
4(1h)-pteridinone, 2-amino-7,8-dihydro-6-(hydroxymethyl)-
2-amino-4-hydroxy-6-(hydroxymethyl)-7,8-dihydropteridine
6-pteridinemethanol, 2-amino-7,8-dihydro-4-hydroxy-
7,8-dihydro-6-(hydroxymethyl)pterin
2-amino-4-hydroxy-6-hydroxymethyl-7,8-dihydropteridine
2-amino-6-(hydroxymethyl)-7,8-dihydropteridin-4-one
C01300
2-amino-6-(hydroxymethyl)-7,8-dihydropteridin-4(3h)-one
6-(hydroxymethyl)-7,8-dihydropterin
6-hydroxymethyl-7,8-dihydropterin
DB02119
2QX0
2-amino-6-(hydroxymethyl)-7,8-dihydro-3h-pteridin-4-one
CHEBI:44841
SCHEMBL230712
DTXSID00274264
2-amino-7,8-dihydro-6-(hydroxymethyl)-4(3h)-pteridinone
Q27093187
2-amino-6-(hydroxymethyl)-1,4,7,8-tetrahydropteridin-4-one
b46l5lr2xm ,
unii-b46l5lr2xm
4(3h)-pteridinone, 2-amino-7,8-dihydro-6-(hydroxymethyl)-
PD008538

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

Role	Description
Saccharomyces cerevisiae metabolite	Any fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

Class	Description
dihydropterin
dihydropterin
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

Pathway	Proteins	Compounds
Folate Biosynthesis	11	26
GTP Degradation and Molybdenum Cofactor Biosynthesis	10	20
Tetrahydrofolate Biosynthesis	8	29
superpathway of tetrahydrofolate biosynthesis	10	29
tetrahydrofolate biosynthesis II	12	32
6-hydroxymethyl-dihydropterin diphosphate biosynthesis I	4	17

Bioassays (2)

Assay ID	Title	Year	Journal	Article
AID1682980	Binding affinity to Escherichia coli BL21 (DE3) HPPK in presence of ATP and MgCl2 by fluorimetry	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Bisubstrate inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: Transition state analogs for high affinity binding.
AID1146850	Inhibition of Escherichia coli dihydroneopterin aldolase assessed as [14C]glycolaldehyde formation using [14C]neopterin substrate by scintillation counting	1977	Journal of medicinal chemistry, Sep, Volume: 20, Issue:9	Inhibitors of folate biosynthesis. 1. Inhibition of dihydroneopterin aldolase by pteridine derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (5.88)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (35.29)	29.6817
2010's	9 (52.94)	24.3611
2020's	1 (5.88)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
piperidine [no description available]	2.31	1	azacycloalkane; piperidines; saturated organic heteromonocyclic parent; secondary amine	base; catalyst; human metabolite; non-polar solvent; plant metabolite; protic solvent; reagent
alpha,beta-methyleneadenosine 5'-triphosphate alpha,beta-methyleneadenosine 5'-triphosphate: do not confuse with beta,gamma-methylene ATP; RN given refers to parent cpd	2.03	1	nucleoside triphosphate analogue
pyrophosphate Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.	2.02	1	diphosphate ion
calcimycin Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.	2.06	1	benzoxazole
piperidines Piperidines: A family of hexahydropyridines.	2.31	1
dihydroneopterin triphosphate [no description available]	2.07	1	dihydropterin; neopterins; pterin phosphate	Escherichia coli metabolite; mouse metabolite
guanine [no description available]	7.1	1	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
sapropterin sapropterin: RN given refers to parent cpd; co-factor required for catalytic activity of nitric oxide synthases. (6R)-5,6,7,8-tetrahydrobiopterin : A 5,6,7,8-tetrahydrobiopterin in which the stereocentre at position 6 has R-configuration.. sapropterin : A tetrahydropterin that is 2-amino-5,6,7,8-tetrahydropteridin-4(3H)-one in which a hydrogen at position 6 is substituted by a 1,2-dihydroxypropyl group (6R,1'R,2'S-enantiomer).	2.06	1	5,6,7,8-tetrahydrobiopterin	coenzyme; cofactor; diagnostic agent; human metabolite
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	2.75	3	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
5,6,7,8-tetrahydromethanopterin [no description available]	2.07	1	tetrahydromethanopterin
neopterin [no description available]	2.07	1
5,6,7,8-tetrahydrofolic acid 5,6,7,8-tetrahydrofolic acid: RN given refers to (DL)-isomer	2.07	1	tetrahydrofolic acid
7,8-dihydropterin 7,8-dihydropterin: RN given refers to parent cpd	1.95	1	organic molecular entity; pterins

Condition	Relationship Strength	Studies
Anoxemia [description not available]	2.06	1
Pulmonary Hypertension [description not available]	2.06	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.06	1
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	2.06	1
Chronic Illness [description not available]	2.06	1
Anterior Cervical Pain [description not available]	2.06	1
Degenerative Disc Disease [description not available]	2.06	1
Acute Post-operative Pain [description not available]	2.06	1
Pseudarthrosis A pathologic entity characterized by deossification of a weight-bearing long bone, followed by bending and pathologic fracture, with inability to form normal BONY CALLUS leading to existence of the false joint that gives the condition its name. (Dorland, 27th ed)	2.06	1
Cervical Spondylosis [description not available]	2.06	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.06	1
Pain, Postoperative Pain during the period after surgery.	2.06	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.06	1
Neck Pain Discomfort or more intense forms of pain that are localized to the cervical region. This term generally refers to pain in the posterior or lateral regions of the neck.	2.06	1
Spondylosis A degenerative spinal disease that can involve any part of the VERTEBRA, the INTERVERTEBRAL DISK, and the surrounding soft tissue.	2.06	1
Intervertebral Disc Degeneration Degenerative changes in the INTERVERTEBRAL DISC due to aging or structural damage, especially to the vertebral end-plates.	2.06	1
Black Death [description not available]	2.03	1
Plague An acute infectious disease caused by YERSINIA PESTIS that affects humans, wild rodents, and their ectoparasites. This condition persists due to its firm entrenchment in sylvatic rodent-flea ecosystems throughout the world. Bubonic plague is the most common form.	7.03	1

chemdatabank.com